Professor Kristen Radford leads the Cancer Immunotherapies Group at Mater Research, University of Queensland at the Translational Research Institute (TRI) in Brisbane Australia.  Her research is focussed on understanding the biology of human dendritic cells in health and disease and translating this knowledge to develop new immunotherapies. She first characterised the rare human cDC1 dendritic cell subtype that is required for inducing anti-tumour and anti-viral immune responses and is now pursuing the therapeutic potential of this discovery to develop novel cancer vaccines.  Prof Radford has published 59 papers and attracted over $7 million in national and international funding. Her work has been recognised by many awards including NSW Young Australian of the Year, NHMRC CDF2 Fellowship, the Sr Regis Mary Dunne Medal for Outstanding Research Contribution. Prof Radford co-leads the Mater Cancer Program and is a Fulbright Future Scholar and Visiting Professor at the Tisch Cancer Institute, Mount Sinai, New York. She also founded the Humanized Mouse Program at TRI, which uses innovative next-generation models for understanding human immunology and more rapid and reliable preclinical immunotherapy drug development.